VSIR and prostate carcinoma: Prostate-cancer patients treated with anti-CTLA-4 (ipilimumab) showed an increased expression of PD-L1 and VISTA by immune cells, suggesting that VISTA may be a compensatory inhibitory pathway after ipilimumab treatment.